BioLamina, a Stockholm-based biotech, has secured a €20M loan from the European Investment Bank to expand its laminin protein technologies. The company produces full-length human recombinant laminin proteins used as cell culture matrices for growing stem cells in therapeutic applications. These matrices support development of cell therapies targeting type 1 diabetes, Parkinson's disease, heart failure, and cancer. The funding also supports animal-free drug safety testing methods. This is BioLamina's first disclosed debt financing and falls under the EIB's BioTechEU mandate to mobilize €10B in biotech investment across 2026–27.
Sort: